
Kelly Fanning on Redefining Leadership—and Balance—for Working Moms
Women make up nearly half of the U.S. workforce but still take on a larger share of household responsibilities. The 2022 American Time Use Survey from the Bureau of Labor Statistics found that women spend more time on average on household activities and child care than men.
The Gender Equality Policy Institute's analysis of the ATU survey found that women who work full time do 1.8 times as much housework as men who work full time. Women who work part-time do 2.5 times as much housework as their male counterparts. Among full-time working parents, women do 1.6 times as much child care and household work as fathers. Part-time working mothers do 2.4 times as much child care and household labor as part-time working fathers.
Kelly Fanning is on a mission to change corporate culture by normalizing those struggles that many working moms face.
Fanning started her career at Johnson & Johnson, where she rose in ranks over 15 years from field sales to corporate leadership. She said that starting from the ground up in retail was the origin of her passion for consumer products, telling Newsweek that this experience brought her close to the shopper.
About a decade into her career, she moved out of the field into the corporate side of the business. That path was through marketing, which meant getting her MBA at Northeastern part-time from 2009 to 2011. Fanning said this move was the biggest career step she had made.
"When I went into marketing, that's the center of running the profit and loss statement, or the P and L, for the company and so it was an incredible opportunity to see the inside of an organization in a way that I had never seen before," she said. "But it also refilled my passion for the consumer, because it's so insight-based and consumer-based when you build a marketing campaign."
She worked as a sales strategy manager and senior brand manager before becoming the director of marketing and sales strategy in 2016. After a stint as the chief of staff and strategy initiatives for the North America president, and the birth of her second son, Fanning took on the role of senior director of consumer strategy for the skin care and beauty division of Johnson & Johnson.
In 2019, Fanning left the company to work at Bayer for about five years. She said she was brought on to turn around teams. But she missed the culture and the beauty industry she fell in love with. After reaching out to her mentors, she left Bayer for The Estee Lauder Company as the senior vice president and general manager for Clinique, North America. She now oversees brands like Clinique, Origins and Dr. Jart+.
Women's Global Impact: Kelly Fanning
Women's Global Impact: Kelly Fanning
Newsweek Illustration
With two young sons and a husband who also works full-time, Fanning knows a thing or two about balance.
"A lot of the times when I speak at events, I give some perspective [that] both the spouses can do it," she said. "You can both have great careers and make it work. Along the way, you make sacrifices and you tend to race to the calendar for first-come, first-served."
She is also the first to admit that being a working parent, while rewarding, is not easy.
Her passion for her work in brand marketing drives her, even in those more difficult moments. She commutes into New York City from northern New Jersey because it's important for her to be in the office. But that also means she might miss a school play or a baseball game.
"I've learned too late in life about finding the balance of passion and performance," she said. "I think about it in the sense of debits and credits – there are days where I'm the best leader [at work] and I'm not as great as a mom, and there are days where I'm the best mom, I can't put in as much [at work]. It's all about the longer-term performance on both."
In corporate America, many women believe there is a culture that appears to treat working mothers and fathers differently.
A PEW study found that women earned an average of 85 percent of what men earned in 2024. Of the women surveyed for this report, 45 percent said a major contributor to the prevalent wage gap is the choices that women make about how to balance work and family. Women, according to PEW, are more likely to feel "a great deal of pressure" to focus on responsibilities at home, when compared to men.
Fanning is no stranger to this feeling and makes it a point to be open and direct with managers and colleagues in the workplace. When she interviewed for her current role, she asked how commuting and family commitments would fit with the job expectations.
She has been honest about having to leave in the middle of a meeting to catch a train back home or pass something off because she needs to attend her son's graduation at 9 a.m.
"I think that you have to be strong enough to protect your time, to protect your schedule, and you have to be really open with others that, whether you're a working caregiver or whatever it is, everyone's time is the most valuable thing we have," she said. "We have to be able to push back and not worry and overthink it."
Maintaining that balance means making the most of her time. Because it is limited, Fanning said her 30-minute impact might have to be as much as another person's one-hour impact.
Being open about the struggles of being a working parent has also led Fanning to be passed over for opportunities like traveling for a work trip because colleagues thought she wouldn't want to be pulled away from her family. She noted that this type of behavior is more common with women in the workplace, as they are still seen as the primary caregivers.
"I want to make the choice not to travel, versus someone else making that choice for me," she said. "And it's really important that as female leaders, we speak up to that in particular [because] not asking me to go on that trip wasn't done because they didn't want me to go. It was done because they thought they were doing me a favor, so I didn't have to say no. And I always want to be seen as having the ability and the strength to say no."
Fanning wants to take the stigma and the guilt out of those decisions because she said the choice to attend a family event shouldn't feel like a hard choice. As she's moved up in leadership, Fanning has led by example and been vocal in the workplace to support other female colleagues and establish an inclusive, supportive and flexible culture.
"Culturally, to have managers and leaders who say, 'no, go [to the graduation]' is so great and reinforces the positivity and takes that [stigma] away," she said. "It's super important to shape that culture and make it the norm."
There have been times when Fanning has repeated in several meetings that she won't be available on a certain day because she has a family obligation. That way, when an expecting parent is faced with that choice in the future, they feel comfortable making it.
Something Fanning often shares with peers is to take the aspects you love about leadership and culture from previous organizations and implement those bits where you can at your current job.
"One of my biggest jobs as a leader is to set a culture and tone in which I want to work in," she said. "You can pay it forward and make the next organization, the next generation better."
Mentorship has played a major role in Fanning's career. She remembers when she felt insecure about her ability to meet the challenge of a new role, and a mentor told her, "They would never have put you in that job if they didn't think you could do it."
"I think sometimes you feel like you're going to fail, and when you realize that an organization, your leadership team, is there to make you succeed, just that shift in mindset, I wish I would have known that earlier in my career," she said. "So often you feel like 'oh my gosh, I'm going to fail, what if I fail?' and if you could flip that to say 'they put me here to succeed. What is it going to feel like when I succeed?' It's such a pivot on that emotion that I love to share with the next generation."
Fanning will join Newsweek at this year's inaugural Women's Global Impact forum. The August 5 event, hosted at Newsweek's headquarters in New York City, will bring together some of the world's top female executives and connect them with rising stars across industries and job functions.
For more information on the event and entry guidelines, please visit the Women's Global Impact homepage.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


CNBC
7 hours ago
- CNBC
Social Security cost-of-living adjustment may be 2.7% in 2026, new estimates find
Social Security beneficiaries may see a 2.7% cost-of-living adjustment in 2026, according to new estimates from policy experts, based on the latest government inflation data. That projected increase would be higher than the 2.5% adjustment beneficiaries saw in 2025. Social Security implements a cost-of-living adjustment every year to adjust benefits for inflation. The Social Security Administration typically announces the official change for the upcoming year in October. New estimates from both Mary Johnson, an independent Social Security and Medicare policy analyst, and the Senior Citizens League, a nonpartisan senior group, point to a 2.7% COLA for 2026, based on new July inflation data. Last month, Johnson had estimated a 2.7% Social Security COLA for 2026, while the Senior Citizens League had projected 2.6%. Social Security cost-of-living adjustments have averaged 2.6% over the past 20 years, according to the Senior Citizens League. To be sure, there are still two months of inflation data that will be factored into the official COLA calculation for next year. The official Social Security cost-of-living is based on three months' of government inflation data for July, August and September, which is averaged and compared to the same three months for the previous year. The percentage difference from one year to the next determines the COLA. The COLA is calculated based on a subset of the consumer price index, the Consumer Price Index for Urban Wage Earners and Clerical Workers, or CPI-W. The consumer price index was up 2.7% over the past 12 months, according to new July data released by the Bureau of Labor Statistics on Tuesday. The CPI-W was up 2.5% over the last 12 months as of July. Tariffs had just a modest effect on the latest consumer price index data, though the impact of the new policies did show up in several areas including household furnishings and supplies. If tariffs do affect inflation in the coming two months, that may impact the Social Security cost-of-living adjustment for 2026.

USA Today
10 hours ago
- USA Today
2026 Social Security COLA estimated at 2.7%. Why seniors still fall behind.
Social Security recipients are still forecast to see a 2.7% bump in their monthly checks next year, the same as last month's estimate, based on the latest inflation report, a new analysis showed. The Consumer Price Index for Urban Wage Earners and Clerical Workers (CPI-W), the index used to calculate the annual adjustment to Social Security benefits, increased 2.5% in July. Overall inflation rose 2.7%, flat from June. The Federal Reserve's inflation goal is 2%. The annual adjustment, also known as the cost-of-living-adjustment (COLA), to Social Security benefits is meant to help seniors maintain their purchasing power over the years, but that hasn't always worked, said Mary Johnson, an independent Social Security and Medicare policy analyst. "Prices on the items that older Americans use the most remain elevated," she said. Categories that see higher levels of inflation than the overall rate include housing, medical costs, transportation and groceries. According to the Bureau of Labor Statistics' most recent weighting for older consumers, these categories when added together comprise more than 85% of household budgets of consumers age 62 and older. Why is July COLA estimate important? The actual Social Security COLA estimate that the Social Security Administration typically announces in October is based on inflation data in the third quarter, or July, August and September. So July is the first month that will be considered for the 2026 COLA calculation. Here's how COLA is calculated: CPI-W for July, August and September are averaged, and then compared against the average of the same three months in the prior year. The percentage of difference is what the Social Security Administration uses to determine the annual COLA adjustment. CPI-W largely reflects the broad index the Labor Department releases each month, although it sometimes differs slightly. Last month, the overall consumer price index rose 2.7% and the index for urban wage earners increased 2.5%. Social Security's future The Social Security Office of the Chief Actuary estimates President Donald Trump's tax package moves the insolvency date for the Social Security trust fund forward by about three months from 2033 to 2032. Part of that is due to the increase in the standard deduction for those age 65 and older from 2025 through 2028. The higher standard deduction means less overall tax liability for most Social Security beneficiaries, but it also means lower revenues received by the Social Security and Medicare Trust Funds from the taxation of benefits. 'Congressional legislators did not include any provision to replace these program funds that were formerly earmarked for the payment of current Social Security and Medicare benefits,' Johnson said. According to Social Security Trustees, a 25.8% cut in 2034 benefits would be necessary. Johnson calculates a 25.8% reduction could cut lifetime Social Security income for beneficiaries at an average age of 65 in 2025 by $176,400 over a 25-year retirement. How many people receive Social Security benefits? In July, 74.36 million people received Social Security, according to the Social Security Administration. These beneficiaries include retired workers, disabled workers, survivors of deceased workers and those receiving Supplemental Security Income. The average monthly benefit was $1,863.12 in July. Medora Lee is a money, markets, and personal finance reporter at USA TODAY. You can reach her at mjlee@ and subscribe to our free Daily Money newsletter for personal finance tips and business news every Monday through Friday.


Business Wire
14 hours ago
- Business Wire
Bayer and Kumquat Biosciences Enter Global Exclusive License and Collaboration in Precision Oncology
BERLIN & SAN DIEGO--(BUSINESS WIRE)--Bayer and Kumquat Biosciences Inc., a clinical-stage biotech company founded by pioneers of the KRAS pathway, today announced that they have entered into an exclusive global license and collaboration to develop and commercialize Kumquat's KRAS G12D inhibitor. Under the agreement, Kumquat is responsible for the initiation and completion of the Phase Ia study, while Bayer will complete development and commercial activities. Kumquat received U.S. Food and Drug Administration (FDA) clearance of the investigational new drug (IND) for its KRAS G12D inhibitor in July 2025. Under the terms of the agreement, Kumquat will receive up to $1.3 billion, including upfront, clinical and commercial milestones, and additional tiered royalties on net sales. Kumquat retains an exclusive option to negotiate for participating in profit-loss sharing in the US. 'We are constantly evaluating innovative approaches to improve outcomes for patients, focusing on areas of high unmet medical need,' said Juergen Eckhardt, M.D., Head of Business Development and Licensing at Bayer's Pharmaceuticals Division. 'We look forward to collaborating with Kumquat, an accomplished team of experts with deep KRAS insights. Our intent is to explore the development of a potential new treatment option for patients, while further complementing Bayer's robust early precision oncology pipeline.' Oncogenic driver mutations, such as KRAS mutations, are changes in the DNA of genes that drive the development and growth of cancer. These mutations are often identified as key targets for cancer treatment, and their identification offers the opportunity to develop target-specific drugs. KRAS G12D mutations are found most frequently in 37 percent of pancreatic ductal adenocarcinoma (PDAC), 13 percent of colorectal cancer and 4 percent of non-small cell lung cancers. 2 PDAC is the most common type of pancreatic cancer (accounting for 85 percent of cases) and remains one of the most difficult tumors to treat, with patients having few treatment options beyond chemotherapy and the five-year survival rate being less than 10 percent. 3 Pancreatic cancer is the sixth leading cause of cancer-related death worldwide. 4 The incidence continues to rise annually, with projections indicating a 95.4 percent increase in new cases by 2050, potentially reaching a total of 998,663 new cases globally. 4 'KRAS mutations are crucial for cancer development and can be targeted with specific therapies in a more selective manner,' said Dominik Ruettinger, M.D., Ph.D., Global Head of Research and Early Development for Oncology at Bayer's Pharmaceuticals Division. 'KRAS mutations occur in nearly 25 percent of human cancers, yet the most prevalent and oncogenic KRAS (G12D) variant still lacks effective treatment options. We look forward to exploring the investigational KRAS G12D inhibitor, which targets a highly relevant signaling pathway that promotes tumor growth and survival.' 'Since pioneering the direct targeting of KRAS G12C mutation over a decade ago, we have continued to discover innovative strategies to target other KRAS mutants, including KRAS G12D,' said Yi Liu, Chief Executive Officer of Kumquat. 'Advancing our novel KRAS G12D asset into the clinic reflects our commitment to delivering durable therapies for KRAS patients suffering from deadly malignancies such as pancreatic, lung and colorectal cancers. This collaboration with Bayer validates the strength of our platform and the potential of our KRAS G12D candidate to address long-standing unmet needs in oncology. We are thrilled to collaborate with Bayer, who shares our vision and strategy for realizing the benefit of small molecule-based transformative treatments. While advancing optimally our KRAS G12D program through the clinic, this collaboration provides Kumquat the financial resources to accelerate its broader clinical pipeline for long-term value, and position Kumquat to deliver life-changing medicines and achieve sustained growth in the coming years.' About Kumquat Biosciences Kumquat Biosciences is a privately held drug discovery and development company committed to creating life-changing medicines for cancer patients. The company focuses on translating breakthrough science into first-in-class therapeutics. Kumquat brings together an accomplished team and distinguished scientific founder with a proven track record of innovative oncology drug discovery and development. The company launched in 2019 and was funded by OrbiMed, HSG, EcoR1, Lilly Asia Ventures, Roche Venture Fund, and Boxer Capital, and previously entered two major collaborations with Eli Lilly and Takeda. For more information, please visit About Bayer Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. In line with its mission, 'Health for all, Hunger for none,' the company's products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2024, the Group employed around 93,000 people and had sales of 46.6 billion euros. R&D expenses amounted to 6.2 billion euros. For more information, go to Find more information at Follow us on Facebook: ak (2025-0140e) Forward-Looking Statements This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments. 1 Cox AD, Fesik SW, Kimmelman AC, Luo J, Der CJ. Drugging the undruggable RAS: Mission possible? Nat Rev Drug Discov. 2014 Nov;13(11):828-51. doi: 10.1038/nrd4389. Epub 2014 Oct 17. PMID: 25323927; PMCID: PMC4355017. 2 Herdeis L, Gerlach D, McConnell DB, Kessler D. Stopping the beating heart of cancer: KRAS reviewed. Curr Opin Struct Biol. 2021 Dec;71:136-147. doi: 10.1016/ Epub 2021 Jul 22. PMID: 34303932. 3 Tonini V, Zanni M. Pancreatic cancer in 2021: What you need to know to win. World J Gastroenterol 2021; 27(35): 5851-5889 URL: 4 Leiphrakpam PD, Chowdhury S, Zhang M, Bajaj V, Dhir M, Are C. Trends in the Global Incidence of Pancreatic Cancer and a Brief Review of its Histologic and Molecular Subtypes. J Gastrointest Cancer. 2025 Feb 24;56(1):71. doi: 10.1007/s12029-025-01183-2. PMID: 39992560.